|
|
Article: Lixte Biotechnology Holdings Announces Extension of Its Cooperative Research and Development Agreement With The National Institute of Neurological Disorders and Stroke, National Institutes of Health, for Development of Anti-Brain Cancer Drugs.
- Article from:
- PR Newswire
- Article date:
- June 25, 2008
CopyrightCOPYRIGHT 2008 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
EAST SETAUKET, N.Y., June 25 /PRNewswire-FirstCall/ -- Lixte Biotechnology Holdings (BULLETIN BOARD: LIXT) announced today that the National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH) and Lixte Biotechnology Holdings, Inc. extended their Cooperative Research and Development Agreement (CRADA) to develop drugs for the treatment of brain cancers. The CRADA, initiated in March 2006 was extended through September 2009.
Dr. John S. Kovach, President and CEO of Lixte, said, "The scientific interaction with the research team at the Molecular Pathogenesis Unit (MPU), Surgical Neurology Branch, (SNB), NINDS, has been ...
Related newspaper, magazine, and journal articles:
|
|
Article: Lixte Biotechnology Holdings' Lead Compound, ...
PR Newswire;
July 2, 2009 ;
700+ words
... ... PRNewswire-FirstCall/ -- Lixte Biotechnology Holdings (BULLETIN BOARD: LIXT) announced ... cancer types in patients." About Lixte Biotechnology Holdings, Inc.: Lixte Biotechnology Holdings, Inc. is a cancer therapeutics ...
|
|